Marco Pappagallo

Marco Pappagallo

Corporate Officer/Principal chez
Sapienza University of Rome
68 ans
Consumer Services
Health Technology
Health Services

Profil

Marco Pappagallo is the founder of Novapharm Therapeutics, which was founded in 2010.
He held the title of Chief Medical Officer at Novapharm Therapeutics.
Currently, Dr. Pappagallo is a Professor at Sapienza University of Rome.
In the past, he worked as the Director-Chronic Pain at Beth Israel Medical Center, The Johns Hopkins University, and Icahn School of Medicine at Mount Sinai.
He also served as the Director-Pain Research & Professor-Anesthesiology at The Mount Sinai Medical Center, Inc. Additionally, Dr. Pappagallo worked as the Executive Director-Medical Intelligence at Grünenthal USA, Inc. and as a Professor at Albert Einstein College of Medicine, Inc. He was also the Chief Medical Officer at Cersci Therapeutics, Inc. Currently, Dr. Pappagallo is the Chief Clinical Officer at Relmada Therapeutics, Inc. from 2020 to 2023.
Dr. Pappagallo obtained a doctorate degree from The American University of Rome.

Postes actifs de Marco Pappagallo

SociétésPosteDébut
Corporate Officer/Principal -

Anciens postes connus de Marco Pappagallo

SociétésPosteFin
RELMADA THERAPEUTICS, INC. Directeur Technique/Scientifique/R&D 01/01/2023
Corporate Officer/Principal 01/01/2014
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -
Voir l'expérience en détail de Marco Pappagallo

Formation de Marco Pappagallo

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

27

Relations au 1er degré

11

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées11

Consumer Services

Health Services

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Services

Health Technology

Health Technology

Novapharm Therapeutics

  1. Bourse
  2. Insiders
  3. Marco Pappagallo
-40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT